Please ensure Javascript is enabled for purposes of website accessibility

3 Ways Rockwell Medical Inc. Could Turn Things Around

By Keith Speights - Oct 7, 2016 at 9:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma continues to struggle. Here's how things could get better.

Image source: Getty Images.

Things just haven't looked great for Rockwell Medical (RMTI -9.33%) lately. Despite winning FDA approval for iron replacement drug Triferic in early 2015, sales haven't taken off. Rockwell's shares are down over 30% so far this year. It won't be easy for the stock to bounce back, but it's not impossible. Here are three ways Rockwell Medical could turn things around.

1. Add add-on reimbursements for Triferic

The biggest problem by far for Rockwell relates to federal reimbursement levels for Triferic. Rockwell Medical desperately needs what is called a transitional add-on reimbursement for the drug. The Centers for Medicare and Medicaid Services (CMS) typically pays for dialysis treatments in a bundled payment to providers, which means that all services and products used in dialysis are lumped together in one single reimbursement. CMS allows some new treatments, though, to receive an add-on reimbursement that pays 106% of a drug's average selling price for two years. This provides a financial incentive for healthcare providers to adopt new treatments. Winning approval for a transitional add-on reimbursement can be the difference between success and failure for a new drug.

Rockwell is definitely trying. The company's lobbying efforts gained support of several members of Congress. These representatives signed and sent a letter to CMS urging the agency to approve a transitional add-on reimbursement for Triferic. Other groups are also helping. Dialysis providers, who stand to reduce costs by using Triferic, have also appealed to CMS. So have patient advocacy groups, nephrologists, and nurse associations. 

There is precedent for winning CMS over. Amgen (AMGN -0.55%) accomplished last year what Rockwell Medical is trying to do now. The big biotech at first didn't have an add-on reimbursement for IV Sensipar. Amgen picked up support in Congress to pressure CMS just as Rockwell has done. Those efforts paid off, with CMS ultimately granting a transitional add-on reimbursement for Amgen's chronic kidney disease treatment.

Ironically, Amgen could be the biggest loser if Rockwell Medical succeeds in its quest. Dialysis providers who use Triferic won't need Amgen's Epogen nearly as much. When Rockwell Medical's management talks about a $1 billion potential market for Triferic, they're counting on winning market share from Epogen.  

2. Gain ground internationally

While Rockwell needs CMS' assistance to jump-start Triferic sales in the U.S., that's not an issue in other markets. If the company can gain ground internationally, it would definitely help Rockwell turn things around.

There is good news on this front. In March, the China Food and Drug Administration (CFDA) accepted Rockwell's clinical trial application for Triferic. Rockwell Medical CEO Robert Chioini thinks that this application could be approved by the end of 2016.  

Rockwell has teamed up with Wanbang Biopharmaceutical to distribute Triferic in China. Wanbang will help navigate the regulatory approval waters there, which is certainly a plus. Chioini has stated in the past that the Chinese dialysis market will become the largest in the world over the next few years. He's probably right -- and that means a major opportunity for Triferic. 

3. Score a win with Calcitriol

Triferic isn't the only product that is important to Rockwell Medical. Calcitriol also could generate significant revenue for the company. The generic drug, which helps prevent and treat secondary hyperparathyroidism (SHPT) by increasing the absorption of calcium from the diet, received FDA approval back in June 2014.

It's taken a long, long time for Rockwell to get Calcitriol to the point of launching commercially due primarily to manufacturing issues. However, the company now expects to launch Calcitriol in the U.S. by late November.

Calcitriol is projected to achieve peak annual sales of around $48 million. That's not a huge amount, but it's still big for Rockwell Medical, which pulled in total sales of only $55.4 million in all of 2015.  

Is a turnaround likely?

If Rockwell Medical manages to secure CMS approval of a transitional add-on reimbursement for Triferic, picks up international sales, and successfully launches Calcitriol, I have no doubt that the stock will rebound solidly. But can the company pull all of these things off? I think so, but I'm not 100% sure.

One would think that CMS would be crazy not to grant add-on reimbursement for a treatment that could potentially save the federal government money. However, you never know what decision CMS will make. There's also no guarantee about what the CFDA will do. And who knows if another manufacturing issue will emerge with Calcitriol?

There's plenty of uncertainty for Rockwell Medical. I am cautiously optimistic that the company will turn things around. What I don't know is how long that turnaround might take.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rockwell Medical, Inc. Stock Quote
Rockwell Medical, Inc.
RMTI
$1.36 (-9.33%) $0.14
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$243.51 (-0.55%) $-1.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.